These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16208701)

  • 1. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
    Krug LM; Miller VA; Patel J; Crapanzano J; Azzoli CG; Gomez J; Kris MG; Heelan RT; Pizzo B; Tyson L; Sheehan C; Ross JS; Venkatraman E
    Cancer; 2005 Nov; 104(10):2149-55. PubMed ID: 16208701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
    Langer CJ; Stephenson P; Thor A; Vangel M; Johnson DH;
    J Clin Oncol; 2004 Apr; 22(7):1180-7. PubMed ID: 14981103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
    Gasparini G; Gion M; Mariani L; Papaldo P; Crivellari D; Filippelli G; Morabito A; Silingardi V; Torino F; Spada A; Zancan M; De Sio L; Caputo A; Cognetti F; Lambiase A; Amadori D
    Breast Cancer Res Treat; 2007 Mar; 101(3):355-65. PubMed ID: 16850247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
    Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
    Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
    Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J
    Cancer; 2007 Feb; 109(4):732-40. PubMed ID: 17211861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
    Seidman AD; Berry D; Cirrincione C; Harris L; Muss H; Marcom PK; Gipson G; Burstein H; Lake D; Shapiro CL; Ungaro P; Norton L; Winer E; Hudis C
    J Clin Oncol; 2008 Apr; 26(10):1642-9. PubMed ID: 18375893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
    Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
    Hensing TA; Peterman AH; Schell MJ; Lee JH; Socinski MA
    Cancer; 2003 Aug; 98(4):779-88. PubMed ID: 12910523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
    Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP
    J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
    Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
    Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
    Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
    Han JY; Lee DH; Kim HY; Hong EK; Yoon SM; Chun JH; Lee HG; Lee SY; Shin EH; Lee JS
    Cancer; 2003 Nov; 98(9):1918-24. PubMed ID: 14584075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
    Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
    J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
    Clamon G; Herndon J; Kern J; Govindan R; Garst J; Watson D; Green M;
    Cancer; 2005 Apr; 103(8):1670-5. PubMed ID: 15751020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
    Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
    Robert N; Leyland-Jones B; Asmar L; Belt R; Ilegbodu D; Loesch D; Raju R; Valentine E; Sayre R; Cobleigh M; Albain K; McCullough C; Fuchs L; Slamon D
    J Clin Oncol; 2006 Jun; 24(18):2786-92. PubMed ID: 16782917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
    Lara PN; Laptalo L; Longmate J; Lau DH; Gandour-Edwards R; Gumerlock PH; Doroshow JH; Gandara DR;
    Clin Lung Cancer; 2004 Jan; 5(4):231-6. PubMed ID: 14967075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
    Tedesco KL; Thor AD; Johnson DH; Shyr Y; Blum KA; Goldstein LJ; Gradishar WJ; Nicholson BP; Merkel DE; Murrey D; Edgerton S; Sledge GW
    J Clin Oncol; 2004 Mar; 22(6):1071-7. PubMed ID: 15020608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.